RT Journal Article
SR Electronic
A1 Buckley, Rita
T1 ISAR-REACT 4 – Bivalirudin Similar to Abciximab/Heparin in Reducing Ischemic Outcomes in NSTEMI and Has Significantly Less Bleeding
JF MD Conference Express
YR 2011
FD SAGE Publications
VO 11
IS 15
SP 14
OP 15
DO 10.1177/155989771115008
UL http://mdc.sagepub.com/content/11/15/14.abstract
AB A strategy of intravenous abciximab (a glycoprotein [GP] IIb/IIIa inhibitor) plus unfractionated heparin, compared with bivalirudin, an IV direct thrombin inhibitor, failed to improve clinical outcomes and increased the risk of bleeding in patients with acute non-ST-segment elevation myocardial infarction (NSTEMI) who were undergoing percutaneous coronary intervention, according to results of the ISAR-REACT 4 trial [NCT00373451].